Demonstrate and verify the intellegent de novo drug discoverer
| Reference number | |
| Coordinator | ANYO Labs AB |
| Funding from Vinnova | SEK 1 459 000 |
| Project duration | May 2024 - May 2025 |
| Status | Ongoing |
| Venture | Ground-breaking technology solutions |
| Call | Groundbreaking and scalable technology solutions in 2024 |
Purpose and goal
Purpose: This project aims to verify the effectiveness of ANYO Labs´ innovative AI platform for de novo drug discovery. This platform utilizes cutting-edge artificial intelligence to design entirely new drug candidates. Goal: By validating the technology, ANYO Labs aims to establish a commercially viable solution. This will revolutionize drug discovery by enabling the faster development of novel therapies, potentially addressing unmet medical needs and accelerating the fight against disease.
Expected effects and result
This 9-month validation of AI-Powered drug discovery project will rigorously test and validate ANYO Labs´ AI platform, focusing on three key areas: - Generate Novel Drug Candidates (de novo chemistry). - Predict Potency Against Specific Proein Targets. - Estimate Key ADMET Properties. By validating these capabilities, we achieve proof for transformative outcomes: - Faster Drug Discovery. - Reduced Development Costs. - Expanded Chemical Space Exploration. - Democratizing Drug Discovery.
Planned approach and implementation
This 9-month project utilizes a work package structure where we will identify promising drug targets and leverage i-TripleD to predict candidate molecules. Collaborating with a CRO, synthesis, and evaluation of the molecules will be made where i-TripleD´s predictions will be validated against experimental results. Finally, all findings and data will be documented with potential publication. Verified learnings will be integrated back into i-TripleD, enhancing its capabilities.